Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A temperature-sensitive liquid embolic agent (TempSLE) is a novel injectable material used in interventional radiology for vascular embolization procedures. It is primarily composed of poly(N-isopropylacrylamide) (PNIPAAm), sometimes copolymerized with butyl methacrylate or combined with iohexol as a contrast medium and dissolved in saline[5][3]. At low temperatures, TempSLE remains in a liquid state, allowing easy delivery through microcatheters. Upon exposure to body temperature (above 30°C), it rapidly undergoes dehydration and transitions into a gel state within the vasculature, forming an occlusive mass that blocks blood flow to targeted tissues such as tumors or hypervascular lesions[5][2][3]. This phase transition mechanism enables precise localization and minimizes risk of premature solidification inside the catheter. The material is non-toxic, non-adhesive, biocompatible, and can be loaded with chemotherapeutics like oxaliplatin for transcatheter arterial chemoembolization (TACE)[4]. Its use has been demonstrated in animal models for tumor treatment and clinical studies for preoperative tumor devascularization and prostatic artery embolization[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on temperature-sensitive liquid embolic agent.